WuXi Bio selected as constituent of FTSE4Good Index Series
WuXi Biologics (“WuXi Bio”), one of the global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced recently that it has once again been selected as a constituent of the FTSE4Good Index Series, and is the only healthcare sector company among the top 10 constituents in the emerging market category. Created by the global index and data […]
